marketcaparena
Search

    XBIT

    XBiotech Inc.

    Company overview

    Market capitalization
    $65.55M
    Employees
    87
    Latest publication
    2026-09-29
    About XBiotech Inc.

    XBiotech Inc., a biopharmaceutical company, discovers, and develops, True Human monoclonal antibodies for treating various diseases. It develops a pipeline of product candidates targeting inflammatory and infectious diseases. The company is also developing interleukin-1 alpha therapies to various medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and general inflammation. The company was incorporated in 2005 and is headquartered in Austin, Texas.

    Company website

    Financial statements

    Income Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ1 20262026-03-31 · USDQ4 20252025-12-31 · USDQ3 20252025-09-30 · USDQ2 20252025-06-30 · USDQ1 20252025-03-31 · USDQ4 20242024-12-31 · USDQ3 20242024-09-30 · USDQ2 20242024-06-30 · USD
    Total Revenue0USD0USD0USD0USD867,000USD0USD0USD0USD
    Cost Of Revenue332,000USD378,000USD427,000USD439,000USD442,000USD—439,000USD435,000USD
    Gross Profit-332,000USD-378,000USD-427,000USD-439,000USD-442,000USD—-439,000USD-435,000USD
    Research Development5,206,000USD25,358,000USD5,080,000USD5,336,000USD11,619,000USD7,821,000USD7,127,000USD12,984,000USD
    Selling General Administrative1,068,000USD4,397,000USD967,000USD1,000,000USD1,931,000USD927,000USD777,000USD1,982,000USD
    Total Operating Expenses5,942,000USD29,755,000USD6,047,000USD6,336,000USD13,550,000USD8,748,000USD7,904,000USD14,966,000USD
    Operating Income-6,274,000USD-29,755,000USD-6,047,000USD-6,336,000USD-13,550,000USD-8,748,000USD-7,904,000USD-14,966,000USD
    Interest Income914,000USD1,219,000USD1,427,000USD1,530,000USD1,504,000USD2,096,000USD2,369,000USD2,689,000USD
    Interest Expense0USD0USD0USD0USD88,000USD204,000USD203,000USD200,000USD
    Net Interest Income914,000USD1,219,000USD1,427,000USD1,530,000USD1,416,000USD1,892,000USD2,166,000USD2,689,000USD
    Income Before Tax-5,456,000USD-26,816,000USD-5,906,000USD-1,728,000USD-10,855,000USD-10,549,000USD-5,006,000USD-13,031,000USD
    Income Tax Expense49,000USD76,000USD102,000USD28,000USD29,000USD-41,000USD9,000USD-25,000USD
    Tax Provision49,000USD76,000USD102,000USD28,000USD29,000USD-41,000USD9,000USD-25,000USD
    Net Income-5,505,000USD-26,892,000USD-6,008,000USD-1,756,000USD-10,884,000USD-10,508,000USD-5,015,000USD-13,006,000USD
    Net Income From Continuing Ops-5,505,000USD-26,892,000USD-6,008,000USD-1,756,000USD-10,884,000USD-10,508,000USD-5,015,000USD-13,006,000USD
    Ebit-6,274,000USD-26,816,000USD-5,906,000USD-1,728,000USD-10,767,000USD-10,345,000USD-4,803,000USD-14,966,000USD
    Ebitda-5,942,000USD-26,438,000USD-5,479,000USD-1,289,000USD-10,325,000USD-9,906,000USD-4,364,000USD-14,531,000USD
    Depreciation And Amortization332,000USD378,000USD427,000USD439,000USD442,000USD439,000USD439,000USD435,000USD
    Reconciled Depreciation332,000USD378,000USD427,000USD439,000USD442,000USD439,000USD439,000USD435,000USD
    Total Other Income Expense Net818,000USD2,939,000USD141,000USD4,608,000USD2,695,000USD-1,801,000USD2,898,000USD1,935,000USD
    Selling And Marketing Expenses———————435,000USD
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Income Yearly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricFY 20252025-12-31 · USDFY 20242024-12-31 · USDFY 20232023-12-31 · USDFY 20222022-12-31 · USDFY 20212021-12-31 · USDFY 20202020-12-31 · USDFY 20192019-12-31 · USDFY 20182018-12-31 · USD
    Total Revenue0USD0USD300,000USD4,010,000USD18,394,000USD43,997,000USD12,681,000USD0USD
    Cost Of Revenue1,686,000USD1,745,000USD1,744,000USD651,000USD5,820,000USD34,548,000USD2,361,000USD2,433,000USD
    Gross Profit-1,686,000USD—-1,744,000USD3,359,000USD12,574,000USD9,449,000USD-2,361,000USD-2,433,000USD
    Research Development47,390,000USD37,757,000USD32,848,000USD31,544,000USD28,268,000USD9,527,000USD24,090,000USD15,725,000USD
    Selling General Administrative8,295,000USD4,714,000USD4,662,000USD6,305,000USD9,388,000USD18,198,000USD7,143,000USD5,269,000USD
    Unclassified Operating Expenses-1,686,000USD—————-2,361,000USD—
    Total Operating Expenses53,999,000USD42,471,000USD37,510,000USD37,849,000USD37,656,000USD27,725,000USD28,872,000USD20,994,000USD
    Operating Income-55,685,000USD-42,471,000USD-37,510,000USD-34,490,000USD-25,082,000USD-18,276,000USD-31,233,000USD-20,994,000USD
    Interest Income5,679,000USD9,812,000USD10,290,000USD3,823,000USD467,000USD2,456,000USD564,000USD400,000USD
    Interest Expense88,000USD807,000USD0USD902,000USD1,087,000USD8,945,000USD748,798,000USD0USD
    Net Interest Income5,591,000USD9,005,000USD10,290,000USD3,823,000USD467,000USD2,456,000USD564,000USD400,000USD
    Income Before Tax-45,305,000USD-38,563,000USD-24,313,000USD-33,588,000USD-25,458,000USD-12,827,000USD718,453,000USD-21,138,000USD
    Income Tax Expense235,000USD-32,000USD244,000USD-688,000USD-8,044,000USD-1,606,000USD49,824,000USD-144,000USD
    Tax Provision235,000USD-32,000USD921,000USD-688,000USD-8,044,000USD-1,606,000USD49,824,000USD—
    Net Income-45,540,000USD-38,531,000USD-24,557,000USD-32,900,000USD-17,414,000USD-11,221,000USD668,629,000USD-21,138,000USD
    Net Income From Continuing Ops-45,540,000USD-38,531,000USD-23,125,000USD-32,900,000USD-17,414,000USD-11,221,000USD668,629,000USD-21,138,000USD
    Ebit-55,685,000USD-37,756,000USD-24,313,000USD-34,490,000USD-25,082,000USD-18,276,000USD718,453,000USD-21,138,000USD
    Ebitda-53,999,000USD-36,011,000USD-22,569,000USD-31,876,000USD-22,434,000USD-16,038,000USD720,814,000USD-18,705,000USD
    Depreciation And Amortization1,686,000USD1,745,000USD1,744,000USD2,614,000USD2,648,000USD2,238,000USD2,361,000USD2,433,000USD
    Reconciled Depreciation1,686,000USD1,745,000USD1,753,000USD2,614,000USD2,648,000USD2,238,000USD2,361,000USD2,433,000USD
    Total Other Income Expense Net10,380,000USD3,908,000USD13,197,000USD902,000USD-376,000USD5,449,000USD749,686,000USD-144,000USD
    Non Operating Income Net Other———902,000USD-376,000USD5,449,000USD749,686,000USD-144,000USD
    Net Income Applicable To Common Shares———-32,900,000USD-17,414,000USD-11,221,000USD668,629,000USD-21,138,000USD
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Balance sheet Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ2 20262026-06-30 · USDQ1 20262026-03-31 · USDQ4 20252025-12-31 · USDQ3 20252025-09-30 · USDQ2 20252025-06-30 · USDQ1 20252025-03-31 · USDQ4 20242024-12-31 · USDQ3 20242024-09-30 · USD
    Total Assets133,651,000USD139,836,000USD150,082,000USD172,424,000USD178,682,000USD181,864,000USD199,093,000USD209,851,000USD
    Cash And Equivalents109,528,000USD———————
    Total Current Assets111,159,000USD117,049,000USD126,953,000USD148,951,000USD154,889,000USD157,685,000USD174,567,000USD185,034,000USD
    Other Current Assets1,340,000USD1,288,000USD1,042,000USD1,134,000USD1,313,000USD1,150,000USD1,032,000USD1,045,000USD
    Total Liabilities5,190,000USD———————
    Total Current Liabilities3,353,000USD2,999,000USD7,929,000USD3,565,000USD3,857,000USD5,410,000USD15,105,000USD15,992,000USD
    Other Current Liabilities2,248,000USD———————
    Total Stockholder Equity128,461,000USD135,017,000USD140,350,000USD167,080,000USD173,064,000USD174,713,000USD182,268,000USD192,115,000USD
    Total Equity Including Noncontrolling Interest128,461,000USD———————
    Property Plant Equipment Net22,492,000USD22,787,000USD23,129,000USD23,473,000USD23,793,000USD24,179,000USD24,526,000USD24,817,000USD
    Accounts Payable1,105,000USD857,000USD1,535,000USD1,043,000USD1,431,000USD1,100,000USD2,223,000USD1,506,000USD
    Common Stock277,071,000USD276,899,000USD276,727,000USD276,565,000USD276,541,000USD276,434,000USD273,105,000USD272,444,000USD
    Retained Earnings-148,610,000USD-141,882,000USD-136,377,000USD-109,485,000USD-103,477,000USD-101,721,000USD-90,837,000USD-80,329,000USD
    Total Liab—4,819,000USD9,732,000USD5,344,000USD5,618,000USD7,151,000USD16,825,000USD17,736,000USD
    Other Current Liab—2,035,000USD6,318,000USD2,422,000USD2,410,000USD4,303,000USD2,632,000USD2,742,000USD
    Capital Stock—276,899,000USD276,727,000USD276,565,000USD276,541,000USD276,434,000USD273,105,000USD272,444,000USD
    Cash—115,459,000USD125,551,000USD147,367,000USD152,938,000USD155,897,000USD172,677,000USD183,118,000USD
    Cash And Short Term Investments—115,459,000USD125,551,000USD147,367,000USD152,938,000USD155,897,000USD172,677,000USD183,118,000USD
    Net Debt—-115,459,000USD-125,551,000USD-147,367,000USD-152,938,000USD-155,897,000USD-162,427,000USD-173,118,000USD
    Net Receivables—302,000USD360,000USD450,000USD638,000USD638,000USD858,000USD871,000USD
    Property Plant Equipment Gross—22,787,000USD44,799,000USD23,473,000USD23,793,000USD24,179,000USD44,511,000USD24,817,000USD
    Common Stock Shares Outstanding—30,487,731shares30,487,731shares30,487,731shares30,487,731shares30,487,731shares30,460,980shares30,472,557shares
    Non Current Assets Total—22,787,000USD23,129,000USD23,473,000USD23,793,000USD24,179,000USD24,526,000USD24,817,000USD
    Non Current Liabilities Total—1,820,000USD1,803,000USD1,779,000USD1,761,000USD1,741,000USD1,720,000USD1,744,000USD
    Net Working Capital—114,050,000USD119,024,000USD145,386,000USD151,032,000USD152,275,000USD159,462,000USD169,042,000USD
    Unclassified Non Current Liabilities—1,820,000USD1,803,000USD1,779,000USD1,761,000USD1,741,000USD1,720,000USD1,744,000USD
    Unclassified Equity—-276,899,000USD-276,727,000USD-276,565,000USD-276,541,000USD-276,434,000USD-273,105,000USD-272,444,000USD
    Short Term Debt—————10,250,000USD10,250,000USD10,000,000USD
    Short Long Term Debt Total—————10,250,000USD10,250,000USD10,000,000USD
    Unclassified Current Liabilities—————-10,243,000USD-10,250,000USD-8,256,000USD
    Short Long Term Debt——————10,250,000USD10,000,000USD
    SourceDisclosureDeterministicFinalLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Balance sheet Yearly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricFY 20252025-12-31 · USDFY 20242024-12-31 · USDFY 20232023-12-31 · USDFY 20222022-12-31 · USDFY 20212021-12-31 · USDFY 20202020-12-31 · USDFY 20192019-12-31 · USDFY 20182018-12-31 · USD
    Total Assets150,082,000USD199,093,000USD226,615,000USD246,103,000USD275,177,000USD353,744,000USD816,877,000USD44,345,000USD
    Other Current Assets1,042,000USD1,032,000USD760,000USD601,000USD934,000USD84,396,000USD3,338,000USD2,386,000USD
    Total Liab9,732,000USD16,825,000USD7,769,000USD5,701,000USD5,792,000USD5,105,000USD61,246,000USD2,947,000USD
    Total Stockholder Equity140,350,000USD182,268,000USD218,846,000USD240,402,000USD269,385,000USD348,639,000USD755,631,000USD41,398,000USD
    Other Current Liab6,318,000USD912,000USD3,501,000USD1,603,000USD1,374,000USD1,351,000USD4,180,000USD1,291,000USD
    Common Stock276,727,000USD273,105,000USD271,152,000USD267,325,000USD262,263,000USD249,805,000USD324,808,000USD279,353,000USD
    Capital Stock276,727,000USD273,105,000USD271,152,000USD267,325,000USD262,263,000USD249,805,000USD324,808,000USD279,353,000USD
    Retained Earnings-136,377,000USD-90,837,000USD-52,306,000USD-27,749,000USD5,151,000USD97,568,000USD430,929,000USD-237,700,000USD
    Cash125,551,000USD172,677,000USD200,023,000USD157,306,000USD236,983,000USD237,366,000USD714,594,000USD15,823,000USD
    Cash And Short Term Investments125,551,000USD172,677,000USD200,023,000USD217,478,000USD236,983,000USD237,366,000USD714,594,000USD15,823,000USD
    Total Current Assets126,953,000USD174,567,000USD201,718,000USD219,843,000USD246,870,000USD325,875,000USD716,263,000USD17,016,000USD
    Total Current Liabilities7,929,000USD15,105,000USD6,100,000USD4,066,000USD3,453,000USD3,984,000USD60,190,000USD2,944,000USD
    Net Debt-125,551,000USD-162,427,000USD-200,023,000USD-157,306,000USD-236,983,000USD-237,366,000USD-714,594,000USD-15,823,000USD
    Net Receivables360,000USD858,000USD935,000USD1,764,000USD8,953,000USD4,113,000USD0USD—
    Accounts Payable1,535,000USD2,223,000USD2,516,000USD2,408,000USD2,069,000USD2,491,000USD2,149,000USD1,653,000USD
    Property Plant Equipment Net23,129,000USD24,526,000USD24,897,000USD26,260,000USD28,308,000USD27,336,000USD25,171,000USD27,329,000USD
    Property Plant Equipment Gross44,799,000USD44,511,000USD43,136,000USD26,260,000USD44,039,000USD27,336,000USD25,171,000USD27,329,000USD
    Common Stock Shares Outstanding30,487,731shares30,460,980shares30,438,459shares30,439,275shares30,043,380shares30,823,458shares46,319,457shares35,804,304shares
    Non Current Assets Total23,129,000USD24,526,000USD24,897,000USD26,260,000USD28,308,000USD27,869,000USD100,614,000USD27,329,000USD
    Non Current Liabilities Total1,803,000USD1,720,000USD1,669,000USD1,635,000USD2,339,000USD1,121,000USD1,056,000USD3,000USD
    Net Working Capital119,024,000USD159,462,000USD195,618,000USD215,777,000USD243,417,000USD321,891,000USD656,073,000USD14,072,000USD
    Unclassified Non Current Liabilities1,803,000USD1,720,000USD1,669,000USD—-1,466,000USD-1,121,000USD——
    Unclassified Equity-276,727,000USD-273,105,000USD-271,152,000USD-267,325,000USD-262,263,000USD-249,805,000USD-324,808,000USD-279,353,000USD
    Short Term Debt—10,250,000USD——————
    Short Long Term Debt—10,250,000USD——————
    Short Long Term Debt Total—10,250,000USD——————
    Unclassified Current Liabilities—-8,530,000USD————49,361,000USD—
    Short Term Investments——0USD60,172,000USD0USD———
    Accumulated Other Comprehensive Income——0USD826,000USD1,971,000USD1,266,000USD-106,000USD-255,000USD
    Other Liab———1,635,000USD2,339,000USD1,121,000USD1,056,000USD3,000USD
    Non Currrent Assets Other———-1,660,000USD-1,091,000USD—75,000,000USD27,329,000USD
    Net Tangible Assets———240,402,000USD269,385,000USD348,639,000USD755,631,000USD41,398,000USD
    Other Assets————-1,000USD533,000USD75,443,000USD—
    Inventory————-8,953,000USD-6,574,000USD——
    Non Current Liabilities Other————1,466,000USD1,121,000USD——
    Current Deferred Revenue——————4,500,000USD—
    Unclassified Non Current Assets——————-75,000,000USD-27,329,000USD
    Unclassified Current Assets———————-1,193,000USD
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Cash flow YTD

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ2 20262026-06-30 · USD
    Depreciation634,000USD
    Stock Based Compensation344,000USD
    Change To Liabilities-4,503,000USD
    Change In Working Capital-771,000USD
    Operating Cash Flow-13,484,000USD
    Capital Expenditures0USD
    Unclassified Investing Cash Flow5,000USD
    Investing Cash Flow5,000USD
    Financing Cash Flow0USD
    Effect Of Forex Changes On Cash-2,544,000USD
    Change In Cash-16,023,000USD
    End Cash Flow109,528,000USD
    SourceDisclosureDeterministicFinal

    Cash flow Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ1 20262026-03-31 · USDQ4 20252025-12-31 · USDQ3 20252025-09-30 · USDQ2 20252025-06-30 · USDQ1 20252025-03-31 · USDQ4 20242024-12-31 · USDQ3 20242024-09-30 · USDQ2 20242024-06-30 · USD
    Net Income-5,505,000USD-26,892,000USD-6,008,000USD-1,756,000USD-10,884,000USD-10,508,000USD-5,015,000USD-13,006,000USD
    Depreciation332,000USD378,000USD427,000USD439,000USD442,000USD439,000USD439,000USD435,000USD
    Stock Based Compensation172,000USD162,000USD24,000USD107,000USD3,329,000USD628,000USD365,000USD379,000USD
    Other Non Cash Items1,304,000USD-1,008,000USD1,202,000USD-3,081,000USD-284,000USD4,100,000USD-707,000USD554,000USD
    Change To Account Receivables58,000USD241,000USD113,000USD-220,000USD220,000USD13,000USD122,000USD-48,000USD
    Change In Working Capital-5,100,000USD4,565,000USD96,000USD-1,698,000USD677,000USD-1,199,000USD-927,000USD262,000USD
    Total Cash From Operating Activities-8,969,000USD-22,952,000USD-4,259,000USD-5,989,000USD-6,720,000USD-6,540,000USD-5,845,000USD-11,376,000USD
    Capital Expenditures0USD-34,000USD-110,000USD-51,000USD-94,000USD-84,000USD-338,000USD-627,000USD
    Free Cash Flow-8,969,000USD-22,986,000USD-4,369,000USD-6,040,000USD-6,814,000USD-6,624,000USD-6,183,000USD-12,003,000USD
    Total Cashflows From Investing Activities9,000USD-34,000USD-110,000USD-51,000USD-94,000USD—-338,000USD-627,000USD
    Net Borrowings0USD0USD0USD0USD-10,250,000USD250,000USD0USD—
    Total Cash From Financing Activities0USD0USD0USD0USD-10,250,000USD283,000USD64,000USD48,000USD
    Change In Cash-10,092,000USD-21,816,000USD-5,571,000USD-2,959,000USD-16,780,000USD-10,441,000USD-5,412,000USD-12,509,000USD
    Begin Period Cash Flow125,551,000USD147,367,000USD152,938,000USD155,897,000USD172,677,000USD183,118,000USD188,530,000USD201,039,000USD
    End Period Cash Flow115,459,000USD125,551,000USD147,367,000USD152,938,000USD155,897,000USD172,677,000USD183,118,000USD188,530,000USD
    Other Cashflows From Investing Activities9,000USD———————
    Investments——-110,000USD-51,000USD-94,000USD-84,000USD-338,000USD-627,000USD
    Issuance Of Capital Stock————0USD———
    Other Cashflows From Financing Activities————33,000USD33,000USD64,000USD48,000USD
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Cash flow Yearly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricFY 20252025-12-31 · USDFY 20242024-12-31 · USDFY 20232023-12-31 · USDFY 20222022-12-31 · USDFY 20212021-12-31 · USDFY 20202020-12-31 · USDFY 20192019-12-31 · USDFY 20182018-12-31 · USD
    Net Income-45,540,000USD-38,531,000USD-24,557,000USD-32,900,000USD-17,414,000USD-11,221,000USD668,629,000USD-21,138,000USD
    Depreciation1,686,000USD1,745,000USD1,744,000USD2,614,000USD2,648,000USD2,238,000USD2,361,000USD2,433,000USD
    Stock Based Compensation3,622,000USD1,753,000USD3,262,000USD5,062,000USD4,463,000USD12,581,000USD3,358,000USD1,660,000USD
    Other Non Cash Items-3,333,000USD5,529,000USD-1,893,000USD2,800,000USD90,000USD90,000USD-674,556,000USD6,526,000USD
    Change To Account Receivables574,000USD77,000USD829,000USD7,340,000USD4,113,000USD-10,687,000USD-4,113,000USD-4,113,000USD
    Change In Working Capital3,640,000USD-1,459,000USD2,719,000USD7,600,000USD79,748,000USD-68,747,000USD-17,618,000USD508,000USD
    Total Cash From Operating Activities-39,920,000USD-30,963,000USD-18,725,000USD-14,824,000USD69,445,000USD-65,149,000USD-18,270,000USD-16,537,000USD
    Capital Expenditures-289,000USD-1,304,000USD-362,000USD-585,000USD-3,525,000USD-3,727,000USD-204,000USD-122,000USD
    Free Cash Flow-40,209,000USD-32,267,000USD-19,087,000USD-15,409,000USD65,920,000USD-68,876,000USD-18,474,000USD-16,659,000USD
    Total Cashflows From Investing Activities-289,000USD-1,304,000USD61,497,000USD-63,892,000USD-3,525,000USD-3,727,000USD674,796,000USD-122,000USD
    Net Borrowings-10,250,000USD10,250,000USD0USD—————
    Total Cash From Financing Activities-10,250,000USD10,450,000USD-9,000USD33,000USD-67,008,000USD-409,724,000USD42,096,000USD201,000USD
    Change In Cash-47,126,000USD-27,346,000USD42,717,000USD-79,677,000USD-383,000USD-477,228,000USD698,771,000USD-15,945,000USD
    Begin Period Cash Flow172,677,000USD200,023,000USD157,306,000USD236,983,000USD237,366,000USD714,594,000USD15,823,000USD31,768,000USD
    End Period Cash Flow125,551,000USD172,677,000USD200,023,000USD157,306,000USD236,983,000USD237,366,000USD714,594,000USD15,823,000USD
    Other Cashflows From Financing Activities-10,250,000USD200,000USD-14,000USD-63,892,000USD427,995,000USD10,276,000USD4,034,000USD201,000USD
    Unclassified Financing Cash Flow10,250,000USD——63,925,000USD-427,995,000USD75,003,000USD71,271,000USD74,802,000USD
    Investments—-1,304,000USD57,705,000USD-63,307,000USD-3,525,000USD-3,727,000USD674,796,000USD-122,000USD
    Unclassified Investing Cash Flow—1,304,000USD-57,705,000USD63,307,000USD3,525,000USD3,727,000USD-674,796,000USD—
    Other Cashflows From Investing Activities——61,859,000USD-63,307,000USD——675,000,000USD—
    Change To Inventory———-8,556,000USD-2,497,000USD-57,535,000USD——
    Change To Liabilities———741,000USD-279,000USD-4,834,000USD53,801,000USD151,000USD
    Dividends Paid———0USD-75,003,000USD-75,003,000USD-75,003,000USD-75,003,000USD
    Cash And Cash Equivalents Changes———-78,716,000USD-1,088,000USD-478,600,000USD698,771,000USD-15,945,000USD
    Sale Purchase Of Stock————7,995,000USD-420,000,000USD41,794,000USD201,000USD
    Issuance Of Capital Stock————0USD—38,062,000USD—
    Exchange Rate Changes——————149,000USD513,000USD
    Unclassified Operating Cash Flow———————-6,526,000USD
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Operating metrics

    No operating metrics are currently published for this company.

    Revenue breakdown

    PeriodDimensionBusiness / regionRevenueCurrencySource
    Q4 2022Quarterly · 2022-12-31ProductClinical Trial Service Revenue0USDLegacy provider
    Q4 2022Quarterly · 2022-12-31ProductManufacturing Revenue300,000USDLegacy provider
    FY 2022Yearly · 2022-12-31ProductClinical Trial Service Revenue0USD0001171843-23-001705
    FY 2022Yearly · 2022-12-31ProductManufacturing Revenue4,010,000USD0001171843-23-001705
    Q3 2022Quarterly · 2022-09-30ProductClinical Trial Service Revenue0USD0001171843-22-007285
    Q3 2022Quarterly · 2022-09-30ProductManufacturing Revenue1,680,000USD0001171843-22-007285
    Q2 2022Quarterly · 2022-06-30ProductClinical Trial Service Revenue0USD0001171843-22-005546
    Q2 2022Quarterly · 2022-06-30ProductManufacturing Revenue1,530,000USD0001171843-22-005546
    Q1 2022Quarterly · 2022-03-31ProductClinical Trial Service Revenue0USD0001171843-22-003510
    Q1 2022Quarterly · 2022-03-31ProductManufacturing Revenue500,000USD0001171843-22-003510
    Q4 2021Quarterly · 2021-12-31ProductClinical Trial Service Revenue0USDLegacy provider
    Q4 2021Quarterly · 2021-12-31ProductManufacturing Revenue4,500,000USDLegacy provider
    FY 2021Yearly · 2021-12-31ProductClinical Trial Service Revenue394,000USD0001171843-22-001904
    FY 2021Yearly · 2021-12-31ProductManufacturing Revenue18,000,000USD0001171843-22-001904
    FY 2021Yearly · 2021-12-31ProductProduct And Service Other0USD0001171843-22-001904
    Q3 2021Quarterly · 2021-09-30ProductClinical Trial Service Revenue19,000USD0001171843-22-007285
    Q3 2021Quarterly · 2021-09-30ProductManufacturing Revenue4,500,000USD0001171843-22-007285
    Q2 2021Quarterly · 2021-06-30ProductClinical Trial Service Revenue25,000USD0001171843-22-005546
    Q2 2021Quarterly · 2021-06-30ProductManufacturing Revenue4,500,000USD0001171843-22-005546
    Q1 2021Quarterly · 2021-03-31ProductClinical Trial Service Revenue350,000USD0001171843-22-003510
    Q1 2021Quarterly · 2021-03-31ProductManufacturing Revenue4,500,000USD0001171843-22-003510
    FY 2020Yearly · 2020-12-31ProductClinical Trial Service Revenue25,975,000USD0001171843-22-001904
    FY 2020Yearly · 2020-12-31ProductManufacturing Revenue18,000,000USD0001171843-22-001904
    FY 2020Yearly · 2020-12-31ProductProduct And Service Other22,000USD0001171843-22-001904

    Periods follow company fiscal calendars. Quarterly, annual and year-to-date amounts are shown separately. Missing values are not zero. Data may be delayed, incomplete or corrected; follow the disclosure links to verify figures.